<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389493</url>
  </required_header>
  <id_info>
    <org_study_id>#5188/#6258R</org_study_id>
    <secondary_id>R01MH045436-02</secondary_id>
    <secondary_id>DSIR 83-ATAS</secondary_id>
    <secondary_id>R01MH045436</secondary_id>
    <secondary_id>R01MH045404</secondary_id>
    <nct_id>NCT00389493</nct_id>
  </id_info>
  <brief_title>Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder</brief_title>
  <official_title>Maximizing Treatment Outcome in OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the short- and long-term effectiveness of two common therapies in
      improving serotonin reuptake inhibitor treatment in people with obsessive-compulsive
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obsessive-compulsive disorder (OCD) is a common psychiatric illness. People with OCD
      experience unwelcome thoughts, known as obsessions, and feel compelled to perform repetitive
      behaviors, or compulsions. Impairment due to OCD symptoms ranges from mild to severe, and
      sometimes can be disabling. The only medications proven effective for OCD are serotonin
      reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience
      significant OCD symptoms, impaired functioning, and diminished quality of life.
      Cognitive-behavioral therapy (CBT), a talking therapy that focuses on altering a person's
      thoughts and behaviors, and the medication risperidone have both been commonly used for
      augmenting SRI treatment for OCD. This study will compare the short- and long-term
      effectiveness of exposure and ritual prevention (EX/RP), a type of CBT, and risperidone in
      augmenting SRI treatment in people with OCD.

      Participants in this double-blind study will be randomly assigned to receive EX/RP,
      risperidone, or placebo in conjunction with their regular SRI medication. All participants
      will remain on their regular SRI at a stable dose. During the first 2 months of the study,
      participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP,
      participants will be exposed to feared objects or ideas, and will be encouraged not to carry
      out a compulsive response. Participants assigned to risperidone or placebo will meet with a
      psychiatrist once every 1 to 2 weeks. At the end of 8 weeks, all participants' OCD symptom
      severity will be assessed. During this time, participants who have responded to treatment
      will continue receiving the same treatment for an additional 24 weeks. Participants assigned
      to EX/RP will meet with a therapist no more than 15 times total, and participants receiving
      risperidone or placebo will meet with a psychiatrist once every 4 weeks. Outcomes will be
      reassessed at study completion.

      Ortho McNeil Janssen Scientific Affairs, LLC are providing medication and placebos for this
      study.

      For information on a related study, please follow this link:

      http://clinicaltrials.gov/show/NCT00045903
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social Adjustment Scale-SR</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (Ham-D)</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brown Assessment of Beliefs (BABS)</measure>
    <time_frame>Week 0 and Week 8</time_frame>
    <description>Scale ranges from 0 to 24 where 0 is &quot;beliefs are false&quot; and 24 is &quot;convinced beliefs = reality&quot;</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive treatment with risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive exposure and ritual prevention therapy (EX/RP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive treatment with the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Dosage of 0.5 mg to 4.0 mg per day as tolerated</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exposure/ritual prevention therapy (EX/RP)</intervention_name>
    <description>EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>EX/RP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be identical in appearance to those of risperidone.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of OCD

          -  Currently on a stable and adequate dose of an SRI

          -  Sufficient severity of symptoms to warrant additional augmentation treatment

        Exclusion Criteria:

          -  Medical or psychiatric conditions that would make participation in the study unsafe

          -  Currently receiving psychotherapy elsewhere at the time of study entry

          -  Previously (within 12 weeks prior to study entry) attended 8 or more sessions of EX/RP
             within a 2-month period or received at least 4 weeks of antipsychotic augmentation
             while on an adequate SRI dose

          -  Currently being treated with an SRI for the first time and has not yet responded, but
             has not tried another SRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blair Simpson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edna Foa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Center for the Treatment and Study of Anxiety</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.columbia-ocd.org/</url>
    <description>Click here for the Columbia University Obsessive-Compulsive Disorder Research Clinic website</description>
  </link>
  <link>
    <url>http://www.med.upenn.edu/ctsa/</url>
    <description>Click here for the University of Pennsylvania Center for the Treatment and Study of Anxiety website</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/show/NCT00045903</url>
    <description>Click here to view the ClinicalTrials.gov record of this trial's parent study</description>
  </link>
  <results_reference>
    <citation>Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.</citation>
    <PMID>24026523</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <results_first_submitted>October 29, 2013</results_first_submitted>
  <results_first_submitted_qc>March 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Augmentation</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Cognitive-Behavioral Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A randomized clinical trial (conducted January 2007-August 2012) at 2 academic outpatient research clinics that specialize in OCD and anxiety disorders. Patients (aged 18-70 years) were eligible if they had OCD of at least moderate severity despite a therapeutic SRI dose for at least 12 weeks prior to entry.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Risperidone</title>
          <description>Participants will receive treatment with risperidone
Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated</description>
        </group>
        <group group_id="P2">
          <title>Treatment With Exposure/Response Prevention</title>
          <description>Participants will receive exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.</description>
        </group>
        <group group_id="P3">
          <title>Treatment With Pill Placebo</title>
          <description>Participants will receive treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Risperidone</title>
          <description>Participants will receive treatment with risperidone
Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated</description>
        </group>
        <group group_id="B2">
          <title>Treatment With Exposure/Response Prevention</title>
          <description>Participants will receive exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.</description>
        </group>
        <group group_id="B3">
          <title>Treatment With Pill Placebo</title>
          <description>Participants will receive treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="10.8"/>
                    <measurement group_id="B2" value="34.3" spread="12.7"/>
                    <measurement group_id="B3" value="33.4" spread="10.4"/>
                    <measurement group_id="B4" value="33.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</title>
        <description>Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Risperidone</title>
            <description>Participants received treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Exposure/Response Prevention</title>
            <description>Participants received exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O3">
            <title>Treatment With Pill Placebo</title>
            <description>Participants received treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.
Mean Y-BOCS score measured at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</title>
          <description>Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Y-BOCS score at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="4.3"/>
                    <measurement group_id="O2" value="27.2" spread="3.9"/>
                    <measurement group_id="O3" value="25.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Y-BOCS score at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="8.8"/>
                    <measurement group_id="O2" value="13.0" spread="6.1"/>
                    <measurement group_id="O3" value="23.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Social Adjustment Scale-SR</title>
        <description>SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Risperidone</title>
            <description>Participants received treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Exposure/Response Prevention</title>
            <description>Participants received exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O3">
            <title>Treatment With Pill Placebo</title>
            <description>Participants received treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.
Mean Y-BOCS score measured at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Social Adjustment Scale-SR</title>
          <description>SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAS-SR at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.4"/>
                    <measurement group_id="O2" value="2.3" spread="0.5"/>
                    <measurement group_id="O3" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAS-SR at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.4"/>
                    <measurement group_id="O2" value="1.9" spread="0.4"/>
                    <measurement group_id="O3" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form</title>
        <description>QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Risperidone</title>
            <description>Participants received treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Exposure/Response Prevention</title>
            <description>Participants received exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
Mean Y-BOCS score measured at week 8</description>
          </group>
          <group group_id="O3">
            <title>Treatment With Pill Placebo</title>
            <description>Participants received treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.
Mean Y-BOCS score measured at week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form</title>
          <description>QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QLESQ-SF Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="14.1"/>
                    <measurement group_id="O2" value="57.8" spread="16.2"/>
                    <measurement group_id="O3" value="56.1" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QLESQ-SF Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" spread="13.9"/>
                    <measurement group_id="O2" value="70.2" spread="14.2"/>
                    <measurement group_id="O3" value="62.6" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Depression Rating Scale (Ham-D)</title>
        <description>Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Risperidone</title>
            <description>Participants will receive treatment with risperidone
Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Exposure/Response Prevention</title>
            <description>Participants will receive exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.</description>
          </group>
          <group group_id="O3">
            <title>Treatment With Pill Placebo</title>
            <description>Participants will receive treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (Ham-D)</title>
          <description>Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ham-D at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="5.6"/>
                    <measurement group_id="O2" value="7.8" spread="6.1"/>
                    <measurement group_id="O3" value="7.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ham-D at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="5.7"/>
                    <measurement group_id="O2" value="7.8" spread="6.1"/>
                    <measurement group_id="O3" value="7.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brown Assessment of Beliefs (BABS)</title>
        <description>Scale ranges from 0 to 24 where 0 is &quot;beliefs are false&quot; and 24 is &quot;convinced beliefs = reality&quot;</description>
        <time_frame>Week 0 and Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Risperidone</title>
            <description>Participants will receive treatment with risperidone
Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated</description>
          </group>
          <group group_id="O2">
            <title>Treatment With Exposure/Response Prevention</title>
            <description>Participants will receive exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.</description>
          </group>
          <group group_id="O3">
            <title>Treatment With Pill Placebo</title>
            <description>Participants will receive treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Brown Assessment of Beliefs (BABS)</title>
          <description>Scale ranges from 0 to 24 where 0 is &quot;beliefs are false&quot; and 24 is &quot;convinced beliefs = reality&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="4.0"/>
                    <measurement group_id="O2" value="6.1" spread="4.6"/>
                    <measurement group_id="O3" value="5.3" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="4.2"/>
                    <measurement group_id="O2" value="2.4" spread="2.9"/>
                    <measurement group_id="O3" value="4.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Risperidone</title>
          <description>Participants received treatment with risperidone Risperidone : Dosage of 0.5 mg to 4.0 mg per day as tolerated Mean Y-BOCS score measured at week 8</description>
        </group>
        <group group_id="E2">
          <title>Treatment With Exposure/Response Prevention</title>
          <description>Participants received exposure and response prevention therapy
Exposure/ritual prevention therapy (EX/RP) : EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
Mean Y-BOCS score measured at week 8</description>
        </group>
        <group group_id="E3">
          <title>Treatment With Pill Placebo</title>
          <description>Participants received treatment with the placebo
Placebo : Placebo capsules will be identical in appearance to those of risperidone.
Mean Y-BOCS score measured at week 8</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Increased thirst</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Impaired Coordination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Extrapyramidal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorgasmia/Erectile Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Changes in breasts</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helen Blair Simpson</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-7000</phone>
      <email>kimeldo@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

